Home/All Molecules/Ranolazine

Ranolazine Range

Comprehensive Ranolazine portfolio for Franchise & Manufacturing.

Category
ranolazine
Total Formulations
3
Available Forms
Tablets

Expand Your Business with Our Multiple Divisions


Browse Ranolazine portfolio by Dosage Form


The Cafoli Advantage for PCD Franchise & Manufacturing

WHO-GMP Quality

Every Ranolazine batch undergoes rigorous in-house and third-party testing, strictly adhering to WHO-GMP standards for efficacy and safety.

Quality Policy

Monopoly & Branding

Secure exclusive PCD franchise rights for your territory and benefit from our range of premium, marketing-driven product packaging.

Market Strategy

Sales Support

Enhance your sales with Cafoli’s complete kit of marketing materials, including visual aids, MR bags, catch covers, and product cards.

Marketing Tools

Ranolazine PCD Pharma Franchise

Ranolazine PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified Ranolazine PCD pharma franchise company offering a portfolio of 3 Ranolazine formulations across sustained-release tablets. Every batch is manufactured at DCGI-approved facilities and supplied to franchise partners with district-level monopoly rights, ready-to-use promotional inputs and dependable stock availability.

What is Ranolazine?

Ranolazine is an antianginal agent that inhibits the late inward sodium current in cardiac myocytes, reducing intracellular sodium and calcium overload and improving ventricular relaxation and myocardial oxygen efficiency. Unlike beta-blockers or nitrates it works without significantly lowering heart rate or blood pressure. The compound record can be reviewed on PubChem.

Therapeutic Applications

Chronic stable angina, usually as add-on therapy when symptoms persist despite beta-blockers, calcium channel blockers or nitrates. It is particularly useful in patients whose blood pressure or heart rate will not tolerate uptitration of conventional antianginals.

Prescribed by: Cardiologists and consulting physicians are the primary prescribers of Ranolazine, typically in chronic coronary artery disease clinics.

Why Ranolazine is a High-Potential Molecule for Distributors

Ranolazine addresses a very specific clinical gap: the stable-angina patient who is still symptomatic but already at the haemodynamic limit of beta-blockers and nitrates. That makes it an add-on rather than a substitute, so it layers onto existing cardiac prescriptions rather than competing with them. India carries a large and growing coronary artery disease burden, prescriptions are chronic and rarely discontinued, and the molecule remains a specialist-driven, relatively low-competition line where a distributor with a cardiology-focused portfolio can build durable value.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers its Ranolazine franchise partners genuine monopoly rights for their allotted district or territory, products manufactured in WHO-GMP certified, DCGI-approved units, and complete promotional support — visual aids, MR bags, sample packs, product cards and doctor gifting. With 1000+ channel partners across India, on-time dispatch and transparent net rates, we make it straightforward to build a profitable Ranolazine business in your region.

References

  1. PubChem – Ranolazine compound record, US National Library of Medicine
  2. PubMed – clinical literature on Ranolazine, NCBI

Aceclofenac in Modern Clinical Practice

Our formulations of Ranolazine find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to:


FAQ about Ranolazine in PCD Franchise

Start Your Ranolazine Franchise with Cafoli Lifecare

Ready to take monopoly rights for Ranolazine in your district? Talk to our franchise team for net rates, packing details and the current availability list. Call 9518447302 or email info@cafoli.in.

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions (FAQs)

Cafoli Lifecare offers 3 Ranolazine formulations in sustained-release tablets. The current list with packing and net rates is shared with registered franchise enquiries.

Yes. Monopoly rights for the Ranolazine range are allotted district-wise on a first-come basis and are confirmed in your franchise agreement, so no other Cafoli partner sells the same brands in your territory.

Cardiologists and consulting physicians are the primary prescribers of Ranolazine, typically in chronic coronary artery disease clinics.

Ranolazine reduces anginal symptoms without meaningfully lowering heart rate or blood pressure, so cardiologists add it on when a patient is still symptomatic but cannot tolerate a higher dose of a beta-blocker, calcium channel blocker or nitrate. Because it is added to existing therapy rather than replacing it, it tends to generate incremental, chronic offtake within a cardiology portfolio.

You need a valid Drug License and a GST registration in your name. Once these are shared along with your territory preference, the Ranolazine franchise agreement and monopoly allotment can be processed.